SPDR SERIES TRUST SPDR S&P BIOTECH ETFSPDR SERIES TRUST SPDR S&P BIOTECH ETFSPDR SERIES TRUST SPDR S&P BIOTECH ETF

SPDR SERIES TRUST SPDR S&P BIOTECH ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪89.48 B‬MXN
Fund flows (1Y)
‪−31.08 B‬MXN
Dividend yield (indicated)
0.18%
Discount/Premium to NAV
−0.09%
Shares outstanding
‪1.13 B‬
Expense ratio
0.35%

About SPDR SERIES TRUST SPDR S&P BIOTECH ETF


Brand
SPDR
Home page
Inception date
Jan 31, 2006
Structure
Open-Ended Fund
Index tracked
S&P Biotechnology Select Industry
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
SSgA Funds Management, Inc.
Distributor
State Street Corp. (Fund Distributor)
XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting scheme
Equal
Selection criteria
Market cap
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
95%4%
Top 10 holdings

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Broaden your horizons with more funds linked to XBI via country, focus, and more.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
XBI trades at 1,528.000 MXN today, its price has fallen −0.42% in the past 24 hours. Track more dynamics on XBI price chart.
XBI net asset value is 1,529.32 today — it's fallen 2.40% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
XBI assets under management is ‪89.48 B‬ MXN. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
XBI price has risen by 6.02% over the last month, and its yearly performance shows a 0.28% increase. See more dynamics on XBI price chart.
NAV returns, another gauge of an ETF dynamics, have risen by −2.40% over the last month, have fallen by −2.40% over the last month, showed a −15.21% decrease in three-month performance and has increased by 3.20% in a year.
XBI fund flows account for ‪−31.08 B‬ MXN (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
XBI invests in stocks. See more details in our Analysis section.
XBI expense ratio is 0.35%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, XBI isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, XBI technical analysis shows the sell rating and its 1-week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating XBI shows the strong sell signal. See more of XBI technicals for a more comprehensive analysis.
Yes, XBI pays dividends to its holders with the dividend yield of 0.18%.
XBI trades at a premium (0.09%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
XBI shares are issued by State Street Corp.
XBI follows the S&P Biotechnology Select Industry. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Jan 31, 2006.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.